Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Farmers Edge Inc. (FDGE.TO) Income Statement Analysis – Financial Results
- Chengdu Tangyuan Electric Co.,Ltd. (300789.SZ) Income Statement Analysis – Financial Results
- SEWON E&C CO., Ltd. (091090.KS) Income Statement Analysis – Financial Results
- Titan Securities Limited (TITANSEC.BO) Income Statement Analysis – Financial Results
- Atlanticus Holdings Corporation 6.125% Senior Notes due 2026 (ATLCL) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
| Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
| Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
| Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
| Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
| Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
| Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
| Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
| Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
| Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
| EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
| EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
| Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
| Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
| Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
| Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
| Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
| Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
| Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
| Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
| EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
| Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company Announces Receipt of Notice from Nasdaq
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
PALO ALTO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products...
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms
PALO ALTO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
PALO ALTO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
PALO ALTO, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024
PALO ALTO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing
PALO ALTO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile
PALO ALTO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
PALO ALTO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the...
Source: https://incomestatements.info
Category: Stock Reports